Articles Archives
Articles
06/24/2026
New eBook: Flexible Infrastructure for Smarter Scale in Advanced Therapies
Advanced therapy developers are being asked to do more with less. Programs need to move faster, reach more patients, support more geographies, and stay ready for evolving regulatory expectations, all while capital remains tightly managed. Cryoport Systems’ new eBook, Flexible Infrastructure: Minimizing CapEx for Smarter Scale in Advanced Therapies, explores that question across the advanced therapy lifecycle. The eBook looks at how developers can preserve capital, reduce operational risk, and avoid overbuilding fixed infrastructure before their programs are ready to use it.
Articles
06/22/2026
Mark Sawicki Joins Base to Base Biotech to Discuss the Future of Cell and Gene Therapy Logistics
Mark Sawicki, President and CEO of Cryoport Systems, recently joined host Jim Cornall on the Base to Base Biotech podcast for a wide-ranging conversation on the evolving cell and gene therapy landscape and the role of specialized supply chain infrastructure in supporting patient access.
Articles
06/17/2026
New ISCT Thought Leadership Explores Why Growth in CGT Demands a Different Operating Model
The way the industry thinks about scale is starting to shift. For decades, growth in biopharmaceutical development has followed a familiar pattern. As programs advance, manufacturing expands and throughput increases, allowing therapies to move from limited, early-phase clinical trial settings into broader patient populations. A new article from Cryoport Systems published through the International Society for Cell & Gene Therapy (ISCT) explores how scale behaves differently in advanced therapies and why the industry may need to rethink the operating models used to support it.
Articles
05/26/2026
Cryoport Systems in Labiotech on Where CGT Supply Chains Start to Break
As more cell and gene therapy programs push toward later-stage trials and commercialization, a familiar set of pressures is starting to surface. What once felt manageable at smaller scale begins to take more effort to hold together as volumes pick up. A recent article in Labiotech, developed in collaboration with Cryoport Systems, looks closely at where that strain comes from and how it often traces back to decisions made much earlier in development.
Articles
05/26/2026
Matthew Plaud on Building Supply Chains that Actually Scale
In a recent conversation with Contract Pharma, Matthew Plaud, COO of IntegriCell® at Cryoport Systems, discussed where advanced therapy supply chains stand today, and where they start to strain as programs move toward commercialization.
Articles
11/07/2025
Cryoport Systems Wins “BioServices Innovation of the Year” for Safepak® Soft System 1800
Cryoport Systems is proud to announce that our Safepak® Soft System 1800 has been named BioServices Innovation of the Year by the prestigious BioTech Breakthrough Awards program. This recognition highlights our continued commitment to advancing cryogenic logistics for cell and gene therapy developers through innovation and excellence when it comes to safety and sustainability.
Supply Chain
10/01/2025
Cryoport Systems Redefines the Global Supply Chain with Launch of New Facility Near Paris, France
Cryoport Systems is thrilled to announce the grand opening of our revolutionary Global Supply Chain Center in Louvre, France. This cutting-edge campus is a one-stop location for end-to-end, temperature-controlled supply chain solutions and is designed to tackle the most complex challenges in the life sciences industry.
Articles
09/13/2025
